Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer
Copyright © 2024 Elsevier B.V. All rights reserved..
OBJECTIVE: Metabolic reprogramming is an important coordinator of tumor development and resistance to therapy, such as the tendency of tumor cells to utilize glycolytic energy rather than oxidative phosphorylation, even under conditions of sufficient oxygen. Therefore, targeting metabolic enzymes is an effective strategy to overcome therapeutic resistance.
MATERIALS AND METHODS: We explored the differential expression and growth-promoting function of MDH2 by immunohistochemistry and immunoblotting experiments in lung cancer patients and lung cancer cells. Pentose phosphate pathway-related phenotypes (including ROS levels, NADPH levels, and DNA synthesis) were detected intracellularly, and the interaction of malate and proteinase 6PGD was detected in vitro. In vivo experiments using implanted xenograft mouse models to explore the growth inhibitory effect and pro-chemotherapeutic function of dimethyl malate (DMM) on lung cancer.
RESULTS: We found that the expression of malate dehydrogenase (MDH2) in the tricarboxylic acid cycle (TCA cycle) was increased in lung cancer. Biological function enrichment analysis revealed that MDH2 not only promoted oxidative phosphorylation, but also promoted the pentose phosphate pathway (PPP pathway). Mechanistically, it was found that malate, the substrate of MDH2, can bind to the PPP pathway metabolic enzyme 6PGD, inhibit its activity, reduce the generation of NADPH, and block DNA synthesis. More importantly, DMM can improve the sensitivity of lung cancer to the clinical drug cisplatin.
CONCLUSION: We have identified malate as a natural inhibitor of 6PGD, which will provide new leads for the development of 6PGD inhibitors. In addition, the metabolic enzyme MDH2 and the metabolite malate may provide a backup option for cells to inhibit their own carcinogenesis, as the accumulated malate targets 6PGD to block the PPP pathway and inhibit cell cycle progression.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:190 |
|---|---|
| Enthalten in: |
Lung cancer (Amsterdam, Netherlands) - 190(2024) vom: 29. Apr., Seite 107541 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun, Mingming [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
53-59-8 |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 16.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.lungcan.2024.107541 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370207084 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370207084 | ||
| 003 | DE-627 | ||
| 005 | 20240416232831.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2024.107541 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1377.xml |
| 035 | |a (DE-627)NLM370207084 | ||
| 035 | |a (NLM)38531154 | ||
| 035 | |a (PII)S0169-5002(24)00074-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sun, Mingming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Malate, a natural inhibitor of 6PGD, improves the efficacy of chemotherapy in lung cancer |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
| 520 | |a OBJECTIVE: Metabolic reprogramming is an important coordinator of tumor development and resistance to therapy, such as the tendency of tumor cells to utilize glycolytic energy rather than oxidative phosphorylation, even under conditions of sufficient oxygen. Therefore, targeting metabolic enzymes is an effective strategy to overcome therapeutic resistance | ||
| 520 | |a MATERIALS AND METHODS: We explored the differential expression and growth-promoting function of MDH2 by immunohistochemistry and immunoblotting experiments in lung cancer patients and lung cancer cells. Pentose phosphate pathway-related phenotypes (including ROS levels, NADPH levels, and DNA synthesis) were detected intracellularly, and the interaction of malate and proteinase 6PGD was detected in vitro. In vivo experiments using implanted xenograft mouse models to explore the growth inhibitory effect and pro-chemotherapeutic function of dimethyl malate (DMM) on lung cancer | ||
| 520 | |a RESULTS: We found that the expression of malate dehydrogenase (MDH2) in the tricarboxylic acid cycle (TCA cycle) was increased in lung cancer. Biological function enrichment analysis revealed that MDH2 not only promoted oxidative phosphorylation, but also promoted the pentose phosphate pathway (PPP pathway). Mechanistically, it was found that malate, the substrate of MDH2, can bind to the PPP pathway metabolic enzyme 6PGD, inhibit its activity, reduce the generation of NADPH, and block DNA synthesis. More importantly, DMM can improve the sensitivity of lung cancer to the clinical drug cisplatin | ||
| 520 | |a CONCLUSION: We have identified malate as a natural inhibitor of 6PGD, which will provide new leads for the development of 6PGD inhibitors. In addition, the metabolic enzyme MDH2 and the metabolite malate may provide a backup option for cells to inhibit their own carcinogenesis, as the accumulated malate targets 6PGD to block the PPP pathway and inhibit cell cycle progression | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 6PGD | |
| 650 | 4 | |a Cisplatin | |
| 650 | 4 | |a Malate | |
| 650 | 4 | |a PPP pathway | |
| 650 | 4 | |a TCA cycle | |
| 650 | 7 | |a DNA |2 NLM | |
| 650 | 7 | |a 9007-49-2 |2 NLM | |
| 650 | 7 | |a Malates |2 NLM | |
| 650 | 7 | |a malic acid |2 NLM | |
| 650 | 7 | |a 817L1N4CKP |2 NLM | |
| 650 | 7 | |a NADP |2 NLM | |
| 650 | 7 | |a 53-59-8 |2 NLM | |
| 700 | 1 | |a Feng, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Qi |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Huifang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Haiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Shuai |e verfasserin |4 aut | |
| 700 | 1 | |a Shan, Changliang |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shuangping |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Jiyan |e verfasserin |4 aut | |
| 700 | 1 | |a Zhai, Hongyan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer (Amsterdam, Netherlands) |d 1994 |g 190(2024) vom: 29. Apr., Seite 107541 |w (DE-627)NLM074973657 |x 1872-8332 |7 nnns |
| 773 | 1 | 8 | |g volume:190 |g year:2024 |g day:29 |g month:04 |g pages:107541 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2024.107541 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 190 |j 2024 |b 29 |c 04 |h 107541 | ||